Shifting CAR-Ts Into a Higher Gear

EPV CAR-T Report 2016

Chimeric antigen receptor T cell (CAR-T) therapy has indisputably become one of the industry’s hottest topics and the next 18 months could see the first CAR-T drugs filed for US approval. But behind the excitement for all things CAR-T lie a number of obstacles in their path to approval.

In its second deep-dive into the CAR-T space EP Vantage explores how much of an advantage it will be for the first company to achieve approval in a market that has never been tested and the ability to charge premium pricing can only be guessed at.

This comprehensive report analyses:

  • The complexity and expense of manufacturing

  • The poor durability of many current CAR constructs

  • The growing ways by which tumour cells can become resistant to CAR-T therapy

  • The fear of severe toxicities

  • The cost and reimbursement questions surrounding CAR-T treatments

SHARE ON TWITTER
SHARE BY EMAIL
SHARE ON LINKEDIN

Download Report